EpiCast Report: Diabetic Retinopathy - Epidemiology Forecast to 2022

LONDON - Dec. 3, 2013 - PRLog -- The total number of diabetic retinopathy prevalent cases in the seven major markets (7MM) — the US, France, Germany, Italy, Spain, UK and Japan — is expected to increase from 4.89 million in 2012 to 7.17 million by 2022, at an Annual Growth Rate (AGR) of 4.68%, forecasts research and consulting firm GlobalData.

The company’s latest report* states that out of the 7MM, Japan and the US had the largest shares of diagnosed prevalent cases of diabetic retinopathy in 2012, with 2.99 million and 2.21 million cases, respectively. This trend will continue by 2022, when Japan will lead the 7MM with 3.55 million people affected by the condition.

Jessica Davies, GlobalData’s Epidemiologist, says: “Diabetic retinopathy is the principal cause of vision impairment in working-age adults throughout the world, and affects a third of diagnosed diabetics. High blood glucose levels in people with poorly-managed diabetes damage the small blood vessels in the retina, and therefore affect the vision.”

The major risk factors of the disease include the duration of diabetes, hyperglycemia, hypertension and dyslipidemia. Additionally, nearly all patients with type 1 diabetes, and an estimated 60% of patients with type 2 diabetes, are affected by diabetic retinopathy within 20 years of developing diabetes.

Davies says: “While the prevalence of diabetes is expected to increase, the incidence and prevalence of diabetic retinopathy should not be expected to grow at the same rate, due to effective management of blood glucose levels, blood pressure and serum lipid levels.”

For Sample Pages, please click or add the below link to your browser:

http://store.globaldata.com/market-reports/pharmaceutical... (http://store.globaldata.com/market-reports/pharmaceutical...)

GlobalData emphasizes the importance of access to the screening and treatment of diabetic retinopathy in order to reduce the burden of diabetes-related vision loss.

“Effective prevention requires knowledge of the magnitude of the problem. Therefore, more prospective population-based studies, along with analysis of the factors mediating the causal pathway of diabetic retinopathy, are vital to comprehending the disease,” the epidemiologist concludes.

This report provides an overview of the risk factors and epidemiological trends for diabetic retinopathy in the seven major markets (7MM) — the US, France, Germany, Italy, Spain, UK, and Japan. It includes a 10-year epidemiological forecast of the diagnosed prevalent cases of diabetic retinopathy in the diagnosed diabetic population segmented by age and sex. This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.

ABOUT GLOBALDATA

GlobalData is the premier source of actionable insight into the energy and healthcare industries. With the combined expertise of more than 1,000 researchers, market analysts and consultants, we provide high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

For further details, please click or add the below link to your browser:

http://store.globaldata.com/market-reports/Pharmaceuticals-and-Healthcare/EpiCast-Report-Diabetic-Retinopathy-Epidemiology-Forecast-to-2022#Report_Title&CompanyID=prlog (http://store.globaldata.com/market-reports/Pharmaceutical...)

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:pressreleases@globaldata.com



North America:          +1 646 395 5477

Europe:          +44 207 753 4299

         +44 1204 543 533

Asia Pacific:          +91 40 6616 6782